Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - Other
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Receivables (2018 - 2022)

China SXT Pharmaceuticals has reported Non-Current Receivables over the past 4 years, most recently at $2.7 million for Q3 2022.

  • For Q3 2022, Non-Current Receivables fell 7.72% year-over-year to $2.7 million; the TTM value through Sep 2022 reached $2.7 million, down 7.72%, while the annual FY2020 figure was $768341.0, N/A changed from the prior year.
  • Non-Current Receivables for Q3 2022 was $2.7 million at China SXT Pharmaceuticals, down from $3.0 million in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $3.0 million in Q3 2021 and troughed at $133757.0 in Q1 2018.
  • A 4-year average of $1.4 million and a median of $768341.0 in 2020 define the central range for Non-Current Receivables.
  • Biggest five-year swings in Non-Current Receivables: soared 542.85% in 2021 and later decreased 7.72% in 2022.
  • Year by year, Non-Current Receivables stood at $133757.0 in 2018, then soared by 246.35% to $463268.0 in 2020, then soared by 542.85% to $3.0 million in 2021, then decreased by 7.72% to $2.7 million in 2022.
  • Business Quant data shows Non-Current Receivables for SXTC at $2.7 million in Q3 2022, $3.0 million in Q3 2021, and $463268.0 in Q3 2020.